-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biological therapy can effectively improve the quality of life and clinical symptoms of patients with moderate to severe psoriasis
.
Risankizumab, a humanized monoclonal antibody that inhibits interleukin (IL)-23, is effective in the treatment of psoriasis and Crohn's disease
Gordonet et al reported the safety of risankizumab by analyzing data from 17 completed or ongoing trials in patients with plaque psoriasis
.
Adverse events were reported as exposure-adjusted event rate (EAER) per 100 patient-years (PY)
Importantly, this study did not identify any new safety signals for risankizumab
.
Inhibition of IL-23 does not predispose patients to bacterial or fungal pathogens, nor does it increase the risk of malignancy
While these findings are encouraging, there are several limitations to consider
.
Although the authors included combined safety data from 17 clinical trials, the generalizability of the results was limited to the population included in the original trial
As the authors acknowledge, loss of patients over time may lead to selection for healthier patients at later time points, which could skew the long-term safety profile of risankizumab
.
Safety data is more than 5 years old and this is the most comprehensive study to date on the safety of risankizumab; however, many safety issues, including cancer, can take decades to develop, so long-term efforts continue to collect Security data is critical
In conclusion, this study provides encouraging data on the safety of risankizumab in the treatment of moderate-to-severe plaque psoriasis
Source: Mirali S, Fabusiwa K, Linos E, Safety in numbers: risankizumab for moderate-to-severe psoriasis.
leave a message here
